Biotech 2012 - Implementation of the USP GMP Potency Bioassay Suite
Date2012-01-26
Deadline2012-01-26
VenuePalo Alto, USA - United States
KeywordsRevised USP 111; USP GMP Potency Bioassay Suite; Potency Bioassays; regulatory requirements; USP Bioassay suite; USP 1032; USP 1033; USP 1034
Topics/Call fo Papers
This webinar on Potency Bioassays will show how to implement the parameters described in the new USP Bioassay suite to deliver compliant assays for Phase I/II, Phase III and commercial products.
Why Should You Attend:
Potency bioassays are a regulatory requirement for release and stability testing of all biopharmaceutical products. Guidelines have remained vague on bioassay expectations due to the large assortment of mechanisms, end points and targets required for these assays. An additional obstacle is the perceived variability of the methods resulting in unacceptable failure rates due to unreliable accuracy, precision and parallelism expectations. The draft USP Bioassay suite consists of the following new chapters: USP 1032, 1033 and 1034). These chapters will be finalized soon and are already being accepted as a coherent data-driven approach to develop, analyze and validate potency assays.
Areas Covered in the seminar:
- Step by step guide to interpreting new USP Bioassay suite.
- Review current expectations for parallelism.
- Decrease failure rate for precision and accuracy.
- Set specifications for the validation protocol and sample analysis.
- Recognize differences between Phase I/II and Phase III Validations.
- Case Studies.
Why Should You Attend:
Potency bioassays are a regulatory requirement for release and stability testing of all biopharmaceutical products. Guidelines have remained vague on bioassay expectations due to the large assortment of mechanisms, end points and targets required for these assays. An additional obstacle is the perceived variability of the methods resulting in unacceptable failure rates due to unreliable accuracy, precision and parallelism expectations. The draft USP Bioassay suite consists of the following new chapters: USP 1032, 1033 and 1034). These chapters will be finalized soon and are already being accepted as a coherent data-driven approach to develop, analyze and validate potency assays.
Areas Covered in the seminar:
- Step by step guide to interpreting new USP Bioassay suite.
- Review current expectations for parallelism.
- Decrease failure rate for precision and accuracy.
- Set specifications for the validation protocol and sample analysis.
- Recognize differences between Phase I/II and Phase III Validations.
- Case Studies.
Other CFPs
- Live Audio Conference on Design Controls: What to know when it comes to FDA regulated industry? By Compliance
- Live Webcast On HIPAA Enforcement and Portable Devices Today -- Are you ready to handle iPads, smart phones, and HHS auditors? By Compliance2go
- Live Webinar On Lyophilization and Stabilization of Proteins, Cells and By Compliance2goViruses
- China: Compliance Processes for Life Science Products (Company Establishment, Clinical Trials, Registrations, Renewals and Supply Chain Considerations
- International Journal of Research in Computer Science, (Volume-2, Issue-2)
Last modified: 2011-12-08 19:49:54